Background Rivaroxaban is a first-line option for the management of venous
thromboembolism (VTE). However, limited data are available regarding its effectiveness in …

There is limited data evaluating clinical outcomes of rivaroxaban versus warfarin in obese
patients with venous thromboembolism (VTE). Our objective was to evaluate the …

Introduction Limited data exist on direct-acting oral anticoagulants in morbidly obese
patients with venous thromboembolism (VTE). We compared clinical and health/economic …

Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …

Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …

Of the 1731 patients in the rivaroxaban arm of this study, 245 patients had a weight > 100
kg but further classification into weight > 120 kg or BMI > 40 kg/m SP 2 sp was not …

Abstract Study Objective Direct oral anticoagulants are the standard of care for venous
thromboembolism (VTE) treatment. These agents are recommended regardless of patient …

Abstract Background Direct oral anticoagulants (DOACs) are the preferred treatment for
venous thromboembolism (VTE). However, DOAC use in patients with a BMI greater than 40 …

Background. Obesity is a major epidemic affecting all age groups in the USA. It has been
associated with venous thromboembolism (VTE), which requires prolonged anticoagulation …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …